相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer
Weiwei Sheng et al.
FASEB JOURNAL (2017)
Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5+CK8+ epithelial cells
Z. Wang et al.
ONCOGENE (2016)
Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma
Saba Mohamed El-Gendi et al.
PATHOLOGY & ONCOLOGY RESEARCH (2016)
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer
Jie Li et al.
CELL CYCLE (2016)
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
Yuan Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63
Toshinori Ozaki et al.
ONCOTARGET (2016)
Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death
M. Nakamura et al.
ONCOGENESIS (2016)
Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine
Claudia Fiorini et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2015)
Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis
Alison Roos et al.
BRITISH JOURNAL OF CANCER (2015)
Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease
Hanna Taipaleenmaeki et al.
CANCER RESEARCH (2015)
Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53
Y. Zhao et al.
CELL DEATH AND DIFFERENTIATION (2015)
Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity
Toshinori Ozaki et al.
FEBS JOURNAL (2015)
Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model
Z. Wang et al.
ONCOGENE (2015)
Runx2, a target gene for activating transcription factor-3 in human breast cancer cells
M. Gokulnath et al.
TUMOR BIOLOGY (2015)
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death
H. Sugimoto et al.
CELL DEATH DISCOVERY (2015)
The RUNX family: developmental regulators in cancer
Yoshiaki Ito et al.
NATURE REVIEWS CANCER (2015)
ΔNp63α enhances the oncogenic phenotype of osteosarcoma cells by inducing the expression of GLI2
Ram Mohan Ram Kumar et al.
BMC CANCER (2014)
Integrin a6 Promotes an Osteolytic Program in Cancer Cells by Upregulating MMP2
Anindita Dutta et al.
CANCER RESEARCH (2014)
MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2
Weiping Li et al.
FEBS LETTERS (2014)
The Activating Transcription Factor 3 Protein Suppresses the Oncogenic Function of Mutant p53 Proteins
Saisai Wei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
RNA interference against MDM2 suppresses tumor growth and metastasis in pancreatic carcinoma SW1990HM cells
Weidong Shi et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2014)
The Prolyl Hydroxylase Inhibitor Dimethyloxalylglycine Enhances Dentin Sialophoshoprotein Expression through VEGF-Induced Runx2 Stabilization
Saeed Ur Rahman et al.
PLOS ONE (2014)
Induced multipotency in adult keratinocytes through down-regulation of ΔNp63 or DGCR8
Deepavali Chakravarti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
Stina Nordh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
miR-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells
Lifeng Miao et al.
ONCOLOGY LETTERS (2014)
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
A. Meijer et al.
BRITISH JOURNAL OF CANCER (2013)
The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells
T. H-Y Leung et al.
BRITISH JOURNAL OF CANCER (2013)
miRNA profiling in pancreatic cancer and restoration of chemosensitivity
Saurabh Singh et al.
CANCER LETTERS (2013)
Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
W. Hanel et al.
CELL DEATH AND DIFFERENTIATION (2013)
Runt-related Transcription Factor 1 (RUNX1) Stimulates Tumor Suppressor p53 Protein in Response to DNA Damage through Complex Formation and Acetylation
Dan Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma
Margaretha van der Deen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma
Matthew R. Ramsey et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis
Rubeta N. Matin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death
Zhiyu Chen et al.
MOLECULAR CANCER (2013)
Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
Bing Song et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Tumor metastasis: moving new biological insights into the clinic
Liling Wan et al.
NATURE MEDICINE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage
T. Ozaki et al.
CELL DEATH & DISEASE (2013)
MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes
S. Nath et al.
ONCOGENESIS (2013)
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells
Chao Zhang et al.
CANCER BIOLOGY & THERAPY (2012)
miR-30 Family Members Negatively Regulate Osteoblast Differentiation
Tingting Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Runx2 Protein Stabilizes Hypoxia-inducible Factor-1α through Competition with von Hippel-Lindau Protein (pVHL) and Stimulates Angiogenesis in Growth Plate Hypertrophic Chondrocytes
Sun-Hee Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma
Johannes C. Lauscher et al.
ONCOLOGY REPORTS (2012)
Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients
Sang Hyub Lee et al.
PATHOLOGY INTERNATIONAL (2012)
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Javier E. Girardini et al.
CANCER CELL (2011)
Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis
Sharanjot Saini et al.
CLINICAL CANCER RESEARCH (2011)
Prognostic Impact of ΔTAp73 Isoform Levels and Their Target Genes in Colon Cancer Patients
Beatriz Soldevilla et al.
CLINICAL CANCER RESEARCH (2011)
miR-301a as an NF-κB activator in pancreatic cancer cells
Zhongxin Lu et al.
EMBO JOURNAL (2011)
Elevated Transcript Levels From the MDM2 P1 Promoter and Low p53 Transcript Levels Are Associated With Poor Prognosis in Human Pancreatic Ductal Adenocarcinoma
Lukasz Filip Grochola et al.
PANCREAS (2011)
A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2
Ying Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy
Bekim Sadikovic et al.
BMC CANCER (2010)
The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS
Wu-Gan Zhao et al.
CARCINOGENESIS (2010)
MicroRNAs and Cellular Phenotypy
Kenneth S. Kosik
CELL (2010)
Regulation of bone development and extracellular matrix protein genes by RUNX2
Toshihisa Komori
CELL AND TISSUE RESEARCH (2010)
Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73γ in lung cancer
Stella Logotheti et al.
FEBS JOURNAL (2010)
Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway
Margareta T. Wilhelm et al.
GENES & DEVELOPMENT (2010)
RUNX3 Modulates DNA Damage-mediated Phosphorylation of Tumor Suppressor p53 at Ser-15 and Acts as a Co-activator for p53
Chizu Yamada et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Runx2 regulates survivin expression in prostate cancer cells
Minyoung Lim et al.
LABORATORY INVESTIGATION (2010)
The Runx transcriptional co-activator, CBFβ, is essential for invasion of breast cancer cells
Daniel Mendoza-Villanueva et al.
MOLECULAR CANCER (2010)
Small RNAs are on the move
Daniel H. Chitwood et al.
NATURE (2010)
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs
Xiaohua Su et al.
NATURE (2010)
A common gain of function of p53 cancer mutants in inducing genetic instability
D. P. Liu et al.
ONCOGENE (2010)
Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions
J. Akech et al.
ONCOGENE (2010)
Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors
A. E. Vilgelm et al.
ONCOGENE (2010)
The p53 orchestra: Mdm2 and Mdmx set the tone
Mark Wade et al.
TRENDS IN CELL BIOLOGY (2010)
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher et al.
NATURE REVIEWS CANCER (2010)
Perspectives on RUNX Genes: An Update
M. Michael Cohen
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2009)
Genetic Control of Bone Formation
Gerard Karsenty et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY (2009)
Recent Advances in Validating MDM2 as a Cancer Target
Elizabeth R. Rayburn et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
Promyelocytic Leukemia Protein is Required for Gain of Function by Mutant p53
Sue Haupt et al.
CANCER RESEARCH (2009)
Ectopic Runx2 Expression in Mammary Epithelial Cells Disrupts Formation of Normal Acini Structure: Implications for Breast Cancer Progression
Jitesh Pratap et al.
CANCER RESEARCH (2009)
Genetic alterations and signaling pathways in the evolution of gliomas
Hiroko Ohgaki et al.
CANCER SCIENCE (2009)
Suppression of Androgen-Independent Prostate Cancer Cell Aggressiveness by FTY720: Validating Runx2 as a Potential Antimetastatic Drug Screening Platform
Chee-Wai Chua et al.
CLINICAL CANCER RESEARCH (2009)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Qing Ji et al.
PLOS ONE (2009)
When mutants gain new powers: news from the mutant p53 field
Ran Brosh et al.
NATURE REVIEWS CANCER (2009)
Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer
Sandra Perez-Torras et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells
Jitesh Pratap et al.
CANCER RESEARCH (2008)
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions
Richard Tomasini et al.
GENES & DEVELOPMENT (2008)
Expression and function of Cbfa-1/Runx2 in thyroid papillary carcinoma cells
Toyoshi Endo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway
William G. Kaelin et al.
MOLECULAR CELL (2008)
Chaperone-dependent stabilization and degradation of p53 mutants
P. Muller et al.
ONCOGENE (2008)
A microRNA signature for a BMP2-induced osteoblast lineage commitment program
Zhaoyong Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1α
Z. G. Peng et al.
ONCOGENE (2008)
Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer
H. Kayed et al.
BRITISH JOURNAL OF CANCER (2007)
Itch inhibition regulates chemosensitivity in vitro
T. M. Hansen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Mutant p53: an oncogenic transcription factor
S. Strano et al.
ONCOGENE (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone
J. Pratap et al.
CANCER AND METASTASIS REVIEWS (2006)
One, two, three -: p53, p63, p73 and chemosensitivity
Martina Mueller et al.
DRUG RESISTANCE UPDATES (2006)
RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer
Zhihai Peng et al.
CLINICAL CANCER RESEARCH (2006)
The E3 ubiquitin ligase Itch controls the protein stability of p63
Mario Rossi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells
Ying Huang et al.
CANCER LETTERS (2006)
Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis
Yuichiro Maruyama et al.
CANCER RESEARCH (2006)
Genetics and biology of pancreatic ductal adenocarcinoma
Aram F. Hezel et al.
GENES & DEVELOPMENT (2006)
The unique NH2-terminally deleted (ΔN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the ΔN variant of p63
ES Helton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis
JW Rocco et al.
CANCER CELL (2006)
The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion
J Pratap et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The RUNX genes: Gain or loss of function in cancer
K Blyth et al.
NATURE REVIEWS CANCER (2005)
The ubiquitin-protein ligase Itch regulates p73 stability
M Rossi et al.
EMBO JOURNAL (2005)
MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy
E Rayburn et al.
CURRENT CANCER DRUG TARGETS (2005)
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity
DY Wei et al.
CANCER RESEARCH (2004)
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
CMR Lima et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma
TK Man et al.
BMC CANCER (2004)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Mono-versus polyubiquitination: Differential control of p53 fate by Mdm2
MY Li et al.
SCIENCE (2003)
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray
A Maitra et al.
MODERN PATHOLOGY (2003)
Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis
T Ishikawa et al.
ONCOGENE (2003)
Functional regulation of p73 and p63: development and cancer
G Melino et al.
TRENDS IN BIOCHEMICAL SCIENCES (2003)
Complex transcriptional effects of p63 isoforms: Identification of novel activation and repression domains
P Ghioni et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
New applications of gemcitabine and future directions in the management of pancreatic cancer
JL Abbruzzese
CANCER (2002)
Live or let die: The cell's response to p53
KH Vousden et al.
NATURE REVIEWS CANCER (2002)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Causal relationship between the loss of RUNX3 expression and gastric cancer
QL Li et al.
CELL (2002)
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage
ER Flores et al.
NATURE (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation
G Fontemaggi et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures
WG Liu et al.
JOURNAL OF CELL BIOLOGY (2001)
Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2
E Zelzer et al.
MECHANISMS OF DEVELOPMENT (2001)
Oncogenes induce and activate endogenous p73 protein
A Zaika et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain
C Gaiddon et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Role of the p53-homologue p73 in EZF1-induced apoptosis
T Stiewe et al.
NATURE GENETICS (2000)
Role for the p53 homologue p73 in E2F-1-induced apoptosis
M Irwin et al.
NATURE (2000)
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
NA Lissy et al.
NATURE (2000)
p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect
MV Blagosklonny
FASEB JOURNAL (2000)
p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells
SL Lai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2000)
分享论文
